

ABPI Disclosure Database Methodological Note 2020

Introduction

STD Pharmaceutical Products Ltd is a small family run business which was formed in 1967 and based in Hereford, UK. The company manufactures Fibrovein, a detergent based sclerosant, which is licensed for the treatment of varicose veins. In July 2019 the company was acquired by Merit Medical Systems, Inc. and all other non-pharmaceutical activities transferred to a new company, Limbco Ltd. STD Pharmaceutical Products continues to hold the MA for Fibrovein and is assisted by employees of Limbco on a transitional basis.

Fibrovein is currently licensed in 30 countries. The arrangement with each country varies but generally there is a distributor and often a local regulatory agent. In the majority of countries, STD Pharmaceutical Products Ltd has little direct interaction with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) or other relevant decision makers (ORDMs) which is largely left to the local distributor.

Methodology

The Managing Director and the Financial Controller of STD Pharmaceutical Products Ltd identified all account codes that could possibly include transfers of value to HCPs, HCOs and ORDMs during the year 2020. All transactions relating to these codes were retrieved and screened to identify relevant transfers of value which have been included in the Disclosure Database of Payments.

The value of transfers was in UK Pounds Sterling. The transfer of values on the template in all instances is the gross amount which may or may not have included VAT and the recipients were responsible for any tax liabilities.

Given the COVID pandemic, there were limited activities and payments during 2020.

STD Pharmaceutical Products Ltd

March 2021